Disclosure of Alzheimers disease biomarker status in subjects with mild cognitive impairment

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 365-368

  Visser, Pieter Jelle ^a   Wolf, Henrike ^b   Frisoni, Giovanni ^c   Gertz, Hermann Josef ^d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimers disease; CSF biomarkers; diagnostic disclosure; mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ABNORMAL LABORATORY RESULT; ALZHEIMER DISEASE; BLOOD ANALYSIS; BRAIN ATROPHY; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FOLLOW UP; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MILD COGNITIVE IMPAIRMENT; NERVE INJURY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGICAL WELL BEING; REFERENCE VALUE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; CEREBROSPINAL FLUID; EDITORIAL; ETHICS; INTERPERSONAL COMMUNICATION; METABOLISM; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DISCLOSURE; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84865466300     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.58     Document Type: Review

References (19)

1. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 67(7), 1201-1207 (2006). (Pubitemid 44563828)
2. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology 75(5), 425-431 (2010).
3. Porteri C, Galluzzi S, Geroldi C, Frisoni GB. Diagnosis disclosure of prodromal Alzheimer disease ethical analysis of two cases. Can. J. Neurol. Sci. 37(1), 67-75 (2010).
4. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69(1), 98-106 (2012).
5. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 7(3), 270-279 (2011).
6. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9(11), 1118-1127 (2010).
7. Scholl M, Wall A, Thordardottir S et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology doi:WNL.0b013-e31825fdf18 (2012) (Epub ahead of print).
8. Migliaccio R, Agosta F, Rascovsky K et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 73(19), 1571-1578 (2009).
9. Van Rossum IA, Visser PJ, Knol DL et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J. Alzheimers Dis. 29(2), 319-327 (2012).
10. Vos S, Van Rossum I, Burns L et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol. Aging doi:0.1016/j. neurobiolaging.2011.12.017 (2012) (Epub ahead of print).
11. Van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion Biomarkers Med. (2012) 6 (4) from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J. Alzheimers Dis. 20(3), 881-891 (2010).
12. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int. Natl J. Clin. Prac. 66(2), 185-198 (2012).
13. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucosepositron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am. J. Neuroradiol. 30(2), 404-410 (2009).
14. Visser PJ. Mild cognitive impairment. In: Principles and Practice of Geriatric Medicine. Sinclair A (Ed.). John Wiley & Sons, UK, 1095-1103 (2006).
15. Van Rossum IA, Vos S, Burns L et al. Injury markers predict cognitive decline in subjects with MCI and amyloid pathology. Neurology (2012) (In press).
16. Galluzzi S, Geroldi C, Ghidoni R et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J. Neurol. 257(12), 2004-2014 (2010).
17. Mattsson N, Andreasson U, Persson S et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7(4), 386-395.e6 (2011).
18. Mollenhauer B, Bibl M, Wiltfang J et al. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid (1-42), and beta-amyloid (1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin. Chem. Lab. Med. 44(2), 192-195 (2006). (Pubitemid 43237964)
19. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ. Couns. 60(3), 301-312 (2006). (Pubitemid 43287935)